BMY- Bristol-Myers Squibb Company
Healthcare · Drug Manufacturers - General
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 24 analysts
12-Month Price Target
$66.21
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $63.64
Graham Number
√(22.5 × EPS × Book Value)
$33.41
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$35.97
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
9/10
90% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
46.6%Return on equity - measures how efficiently capital is used
Positive profit margin
18.9%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+5.7%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+153.1%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
201.86×Low financial leverage reduces risk of distress
Current ratio above 1
1.53×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$717M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
3.96%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Oct 29, 2026
47
days
EPS (TTM)
$4.54
P/E (TTM)
14.0
Fwd P/E
9.7
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
3.96%
5Y Avg Annual
$2.2420
Last Payment
$0.6300
Ex-Date
07/02/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest07/02/2026 | 08/03/2026 | $0.6300 | 3.96% |
04/02/2026 | 05/04/2026 | $0.6300 | 3.96% |
01/02/2026 | 02/03/2026 | $0.6300 | 3.96% |
10/03/2025 | 11/04/2025 | $0.6200 | 3.90% |
07/03/2025 | 08/04/2025 | $0.6200 | 3.90% |
04/04/2025 | 05/06/2025 | $0.6200 | 3.90% |
01/03/2025 | 02/04/2025 | $0.6200 | 3.90% |
10/04/2024 | 11/05/2024 | $0.6000 | 3.77% |
Magic Number
Shares needed to self-fund your next purchase
$63.64
Price
$0.6300
Last div. (quarterly)
102
shares
Own 102 BMY shares ($6,491.28) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$6,491.28
New shares / year
+4 shares
Dividend Calculator
3.96% yieldEstimate BMY dividend income at the current rate.
Per year
$395.98
Per month
$33
≈ 157.1 shares at $2.52/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
BMY vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
Princeton, United States
Employees
32,500
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Bristol-Myers Squibb Company (BMY) stock trades at $63.64, down 0.17% on the day. With a market capitalization of $130.00 billion, BMY is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 14.0, a forward P/E of 9.7 and earnings per share (EPS) of $4.54. Over the most recent period the company reported 6% year-over-year revenue growth and a net profit margin of 18.9%. Below you'll find BMY's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
BMY - Frequently Asked Questions
Is Bristol-Myers Squibb Company (BMY) a good stock to buy in 2026?
Bristol-Myers Squibb Company (BMY) shows strengths such as a strong 19% net margin and a 47% return on equity, while risks include high leverage (debt/equity of 201.9). Whether BMY is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is BMY's stock price today?
Bristol-Myers Squibb Company (BMY) trades at $63.64, down 0.17% on the session. Prices on this page update throughout the trading day.
Does BMY pay a dividend?
Yes. Bristol-Myers Squibb Company pays an annual dividend of $2.52 per share, a dividend yield of 3.96%. The most recent ex-dividend date was July 2, 2026. Its payout ratio is about 55% of earnings.
Is BMY overvalued?
With a P/E ratio of 14.0×, BMY trades at a relatively modest valuation for the healthcare sector. Its PEG ratio is 2.50. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is BMY's market cap?
Bristol-Myers Squibb Company (BMY) has a market capitalization of $130.00 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.